PUBLIC RELEASE DATE:
31-May-2014
Contact: Erika Matich erika.matich@ucdenver.edu 303-524-2780 University of Colorado Denver
At the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs). The drug was generally well tolerated, and several of the 26 patients with advanced solid tumors experienced stable disease for greater than six months. Three trials are now open for OMP-54F28 (FZD8-Fc) in combinations with standard therapy for pancreatic, ovarian and liver cancers, being offered at the CU Cancer Center and elsewhere.
"These are optimistic results for one of the first targeted therapies for cancer stem cells," says Antonio Jimeno, MD, PhD, investigator at the CU Cancer Center, director of the university's Cancer Stem Cell-Directed Clinical Trials Program, and principal investigator of the clinical trial at the CU Cancer Center site. "And it is great to work with such a science-focused sponsor, whose vision aligns with ours: bringing to the clinic cutting-edge drugs and ideas that are focused on targeting CSCs. In the context of the collaboration between the Gates Center for Stem Cell Biology and the CU Cancer Center this was the second clinical trial we offered to our patients with the specific intent to eliminate the CSCs in their tumors."
OMP-54F28 (FZD8-Fc) is an antagonist of the Wnt pathway, a key CSC signaling pathway that regulates the fate of these cells. The Wnt pathway is known to be inappropriately activated in many major tumor types, including colon, breast, liver, lung and pancreatic cancers, and is critical for the function of CSCs. Because of this extensive validation, in the Jimeno lab and elsewhere, the Wnt pathway has been a major focus of anti-cancer drug discovery efforts. OMP-54F28 (FZD8-Fc) and a sister compound also developed by OncoMed, vantictumab (OMP-18R5), are two of the first therapeutic agents targeting this key pathway to enter clinical testing. In multiple preclinical models, OMP-54F28 (FZD8-Fc) has shown its effectiveness in reducing CSC populations, leading to associated anti-tumor activity, either as a single agent or when combined with chemotherapy.
"The ongoing line of work with this drug is an excellent example of the bench getting even closer to the bedside our lab work with the drug in patient-derived xenograft models of disease makes possible the clinical trials taking place at the University of Colorado Hospital next door," Jimeno says.
The Phase I clinical trial of OMP-54F28 (FZD8-Fc) is an open-label dose escalation study in patients with advanced solid tumors for which there was no remaining standard curative therapy. Patients are assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and initial signals of efficacy. The trial is conducted at Pinnacle Oncology Hematology in Scottsdale, Arizona, the University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, and the CU Cancer Center under the direction of Principal Investigators Dr. Michael S. Gordon, Dr. David Smith and Dr. Antonio Jimeno, respectively.
The most common adverse events, mild to moderate and manageable, included dysgeusia (altered taste), fatigue, muscle spasms, decreased appetite, alopecia and nausea. One related Grade 3 or greater adverse event of Grade 3 increased blood phosphorus was reported. One moderate sacral insufficiency fracture occurred in one patient at the highest tested dose of 20 mg/kg every three weeks after 6 cycles.
"The drug is now being developed in combination with standard of care in three Phase 1b clinical trials, with the CU Cancer Center being one of the active sites," Jimeno says. "In pancreatic, ovarian and liver cancers, we hope that by adding anti-cancer stem cell drugs to standard of care, we can control proliferating cells within the tumor that could otherwise help the tumor regenerate in the face of existing chemotherapies."
Continued here:
Results in Phase I trial of OMP-54F28, a Wnt inhibitor targeting cancer stem cells
- Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction -... - January 19th, 2021
- Breakthrough motor neurone disease study finds way to reverse damage - The National - January 19th, 2021
- Orchard Therapeutics Announces 2021 Corporate Priorities Supporting the Build-out of its Commercial Business in Hematopoietic Stem Cell (HSC) Gene... - January 12th, 2021
- Cancer Stem Cell Therapy Market : Information, Figures And Analytical Insights 2020-2026 - LionLowdown - January 5th, 2021
- Paint it all Pink winner charity donation helps Elizabeth Wende Breast Care Fund - MPNnow.com - December 22nd, 2020
- Center for Regenerative Medicine - Mayo Clinic - December 17th, 2020
- Cancer Stem Cell Therapy Market Revenue, Global Forecast, Cost, Key Participants and Emerging Trends and Key Players-AVIVA BioSciences , AdnaGen - The... - December 12th, 2020
- Cancer Stem Cell Therapy Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 - Cheshire Media - December 5th, 2020
- Short Redhead Reel Reviews for the week of Dec. 4 - ECM Publishers - December 5th, 2020
- Human sperm stem cells grown in lab, an early step toward infertility treatment - Jill Lopez - November 18th, 2020
- Global Stem Cell and Primary Cell Culture Medium Industry 2020 Market Research With Size, Growth, Manufacturers, Segments And 2026 Forecasts Research... - November 18th, 2020
- Updated: FDA gives Cellectis all clear after patient death halted off-the-shelf CAR-T trial - Endpoints News - November 18th, 2020
- FUJIFILM Cellular Dynamics and Lonza Agree to Expand the Availability and Use of Induced Pluripotent Stem Cell Technology - BioSpace - November 16th, 2020
- Cleveland Clinic team draws a link between COVID-19 protection and the sleep aid melatonin - FierceBiotech - November 16th, 2020
- Global Cancer Stem Cell Therapy Market Outlook by Types, Applications, End Users and Opportunities to 2025 - TechnoWeekly - November 16th, 2020
- Orphan Drug Designation Granted for CSL Behring's Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Disease - PRNewswire - November 3rd, 2020
- What's On The Ballot? Here's A Look At California's 2020 Propositions - KPBS - November 3rd, 2020
- The Animal Stem Cell Therapy market to witness remarkable disruptions in the next decade - TechnoWeekly - October 28th, 2020
- Dr. Hill on Next Steps for Research Exploring CAR T-Cell Therapy in MCL - OncLive - October 28th, 2020
- Randomized Controlled Study Using Direct Injection of Remestemcel-L Into Inflamed Gut of Patients With Crohn's Disease and Ulcerative Colitis -... - October 24th, 2020
- Stem cells, repair cells, & growth factors: What is the latest? - The Times of India Blog - October 20th, 2020
- Cell Therapy Market Trend,COVID-19 Impact,Current Industry Figures With Demand By Countries And Future Growth - PRnews Leader - October 20th, 2020
- Global and United States Cancer Stem Cell Therapy Market Leading Players Expected to Witness the Highest Growth 2025 | AVIVA BioSciences, AdnaGen,... - October 20th, 2020
- Stem Cell and Primary Cell Culture Medium Market Share, By Product Analysis, Ap - News by aeresearch - October 20th, 2020
- Months after achieving unicorn status, Orca steers into the fast lane with an RMAT designation for cell therapy candidate - Endpoints News - October 15th, 2020
- EdiGene Gets $67 Million Infusion to Bring Gene Editing to the Clinic - BioSpace - October 15th, 2020
- CAR T-cell Therapies for the Treatment of Patients with Acute Lymphoblastic Leukemia - OncoZine - October 15th, 2020
- Bone Therapeutics' allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion -... - October 15th, 2020
- Biopharma Money on the Move: October 7-14 - BioSpace - October 15th, 2020
- Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. - UroToday - October 8th, 2020
- Around Town: Life is a series of choices a look at California's ballot propositions - VVdailypress.com - October 8th, 2020
- League of Women Voters Releases Their Proposition recommendations - Valley Voice - October 8th, 2020
- Expansion Therapeutics Names Renato Skerlj, Ph.D., Chief Executive Officer and President - BioSpace - October 8th, 2020
- What is the difference between ventilation and respiration? - EMS1.com - October 8th, 2020
- Props to you, Californians: A preview of what's on your November ballot - Palo Alto Online - October 8th, 2020
- TreeFrog Therapeutics and Invetech Expand Partnership to Transition High-throughput Stem Cell Encapsulation Technology to GMP System for... - October 8th, 2020
- How to Vote This November: A Progressive's Opinion Redheaded Blackbelt - Redheaded Blackbelt - October 1st, 2020
- Cancer Stem Cell Therapy Market Size is Thriving worldwide with Topmost Companies Like: Advanced Cell Diagnostics, Silicon Biosystems, Cancer Stem... - September 30th, 2020
- Cell Therapy Manufacturing Market to be Worth USD 8 billion by 2030, predicts Roots Analysis - The Daily Chronicle - September 25th, 2020
- Global Stem Cell and Primary Cell Culture Medium Market Research (2015-2026): In-depth Assessment of the Growth and other Aspects - Internet Shots - September 23rd, 2020
- Cellular Therapy Products Market 2020 2025 analysis examined in new C - News by aeresearch - September 23rd, 2020
- Those linked to stem cell board received more than $2.1 billion - Capitol Weekly - September 15th, 2020
- Takeda Expands Cell Therapy Efforts with New R&D Manufacturing Plant in Boston - BioSpace - September 15th, 2020
- Allow your body to heal on its own with the help of Stemcure Clinic - Lowvelder - September 15th, 2020
- The Animal Stem Cell Therapy market to Undergo positive Transformation between 2017 and 2025 - The Daily Chronicle - September 12th, 2020
- Dr. Hill on the Role of CAR T-Cell Therapy in Relapsed/Refractory DLBCL - OncLive - September 12th, 2020
- When old age catches up with you in your 30s - The Standard - August 31st, 2020
- The 9th ISS R&D Conference Is Opening This Week, but This Year's Setup Is Different - Science Times - August 31st, 2020
- Stem Cell Concentration System Market Covid-19 Impact On 2020 In-depth Industry Size, Analysis, Growth, Opportunity and Forecast 2026: EmCyte, Terumo,... - August 28th, 2020
- Degenerative Disc Disease Therapeutics Market Industry Size, Growth, Analysis and Forecast to 2026 Osiris Therapeutics Inc, US Stem Cell Inc, Yuhan... - August 28th, 2020
- Burger Reviews BTK Inhibitors and Beyond in Frontline CLL - Targeted Oncology - August 25th, 2020
- Global Degenerative Disc Disease Therapeutics Market Checkout the Unpredictable Future: Industry Applications, Competitors growth prospects, Industry... - August 25th, 2020
- Adapting ideas from quantum physics to calculate alternative interventions for infection and cancer - Science Codex - August 25th, 2020
- What voters need to know about Californias ballot propositions - OCRegister - August 24th, 2020
- Diabetic patients may find ray of hope in stem cell treatment - The News International - August 21st, 2020
- Jocelyn McGlynn inspired people to help others - Chatham This Week - August 19th, 2020
- Animal Stem Cell Therapy Market with leading companies like ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and... - August 19th, 2020
- Global Stem Cell and Primary Cell Culture Medium Market Report: Production, Revenue, Price Trend by Types & Market Analysis by Application -... - August 18th, 2020
- Hackensack University Medical Center Has the Best Cancer Center in New Jersey John Theurer Cancer Center recognized by U.S. News & World Report -... - August 18th, 2020
- Novel CAR T-Cell Therapy Shows Promise in Advanced Hodgkin Lymphoma - Curetoday.com - August 13th, 2020
- Sapience Therapeutics Announces First Patient Dosed with ST101 in Phase 1/2 Study in Patients with Advanced Unresectable and Metastatic Solid Tumors |... - August 13th, 2020
- Novo backs 'breakthrough' antifungal player's $60M round with a focus on rare mold infections - Endpoints News - August 13th, 2020
- CanSino reaps $748M windfall from Shanghai IPO as it warns Covid-19 vaccine won't be a huge money maker - Endpoints News - August 13th, 2020
- Roche pulls a tumor micro-environment drug out of the freezer, hands it to a UK upstart - Endpoints News - August 13th, 2020
- Avobis Bio and Vineti announce strategic collaboration to support new implantable cell therapies addressing debilitating conditions - GlobeNewswire - August 11th, 2020
- Plotting to be the BridgeBio of AI, Atomwise lands $123 million Series B for hype-heavy platform - Endpoints News - August 11th, 2020
- Strategies and Suggestions for Patent Applications in the Hot Field of Biotechnology - Lexology - August 11th, 2020
- Versant debuts Ridgeline's startup #4, armed with $30M and alternative TCR cell therapies for solid tumors - Endpoints News - August 11th, 2020
- Covid-19 roundup: CureVac beefs up its unicorn IPO dreams as billionaire owner takes this Covid-19 mRNA player on a forced march to Nasdaq; Kodak's... - August 10th, 2020
- Vida Ventures co-leads Dyne's $115M megaround for next-gen oligo therapies aimed squarely at muscles - Endpoints News - August 10th, 2020
- Edited Transcript of BLCM.OQ earnings conference call or presentation 6-Aug-20 9:00pm GMT - Yahoo Finance - August 7th, 2020
- National Stem Cell Clinic: Stem Cell Therapy in Miami ... - August 7th, 2020
- In the clinic for Aug. 6, 2020 | 2020-08-06 - BioWorld Online - August 6th, 2020
- Cell Therapy Manufacturing Market to be Worth USD 8 billion by 2030, predicts Roots Analysis - Bulletin Line - August 5th, 2020
- StemCells 21 Premium Stem Cell Treatments In Bangkok ... - August 5th, 2020
- 'Year of Preparations for the Next Fifty Years' will contribute to country's development process - WAM EN - August 4th, 2020
- MediVet Biologics Rebrands as Ardent Animal Health - PR Web - August 3rd, 2020
- 27th Annual Luau and Legends of Surfing Invitational Set to Make Virtual Waves - UC San Diego Health - July 30th, 2020
- Celsius Therapeutics, Twist Bioscience, And More: News From July 2020 - Bio-IT World - July 30th, 2020
- David Karli Launches New Treatment for Patients with severe Arthritic Conditions - THISDAY Newspapers - July 29th, 2020